U.S. Markets closed
  • S&P 500

    4,395.64
    +41.45 (+0.95%)
     
  • Dow 30

    34,258.32
    +338.48 (+1.00%)
     
  • Nasdaq

    14,896.85
    +150.45 (+1.02%)
     
  • Russell 2000

    2,218.56
    +32.38 (+1.48%)
     
  • Gold

    1,768.40
    -9.80 (-0.55%)
     
  • Silver

    23.03
    +0.46 (+2.05%)
     
  • EUR/USD

    1.1696
    -0.0034 (-0.2924%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    20.87
    -3.49 (-14.33%)
     
  • GBP/USD

    1.3619
    -0.0045 (-0.3282%)
     
  • USD/JPY

    109.7800
    +0.5600 (+0.5127%)
     
  • BTC-USD

    42,760.04
    +436.11 (+1.03%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     
  • Oops!
    Something went wrong.
    Please try again later.

FDA okays Regeneron COVID-19 antibody as preventive in high-risk settings

·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

July 30 (Reuters) - The U.S. Food and Drug Administration has expanded the emergency use authorization of Regeneron Pharmaceuticals Inc's COVID-19 antibody cocktail, enabling its use as a preventive treatment for the illness in certain people. 

  The company said the authorization enables the therapy to be used in people exposed to an infected individual, or who are at high risk of exposure to an infected individual in settings such as nursing homes or prisons. 

  The combo therapy, REGEN-COV, was authorized in November for emergency use to treat people with mild-to-moderate COVID-19 in the United States. 

  REGEN-COV, a combination of casirivimab and imdevimab, protected household contacts from exposure to SARS-CoV-2, with 72% protection against symptomatic infections in the first week, and 93% after that, according to trial data released by the company in April. 

  Regeneron said the expanded authorization will help address the needs of immunocompromised people, including those taking immunosuppressive medicines, whose bodies may not mount an adequate response to COVID-19 vaccination. 

  (Reporting by Mrinalika Roy in Bengaluru; Editing by Devika Syamnath)